secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001650664-23-000005
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine CTO and CBO Bruce Eaton to step down Jan 2, 2024
----------------------------------------------------------------

- Bruce Eaton, EVP, Chief Technology Officer and Chief Business Officer, departs effective January 2, 2024.
- Severance includes 12 months base salary, COBRA contributions, and potential 2023 bonus.
- Stock option exercise extended to January 2, 2025; performance stock units may vest if metrics met by March 31, 2024.
- Separation agreement includes non-disparagement and confidentiality provisions; no successor named.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000005/0001650664-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066423000005/edit-20231003.htm
  HTML page:      https://secwatch.observer/filing/0001650664-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer